Your doctor is neither right nor wrong. Even though routine annual PSA screening for every individual is no longer recommended, patients with certain risk factors may need close followup PSA testing every few years. Without knowing your risk factors, it would be not be possible to determine if you should have PSA performed. Given the current recommendations, certain men over the age of 50 will and should be screened for prostate cancer with PSA testing.
PSA screening for prostate cancer is a controversial topic in the health care community. While studies from Innsbruck, Austria have suggested improved survival for patients who had undergone PSA screening, others would argue that these findings are simply the result of lead-time bias. Two recent studies on the role of PSA screening reached divergent conclusions on PSA screening (published in NEJM 360;13, 2009). The PLCO trial concluded that PSA screening did not reduce prostate cancer mortality, but the ERSPC trial concluded that PSA screening resulted a 20% reduction in prostate cancer mortality. Such divergent conclusions may be due to methodological problems found in the PLCO trial where 40% of "un-screeened" patients actually had PSA testing done.
Currently, there are different recommendations on prostate cancer screening from the American Urologic Association (AUA) and the American Cancer Society (ACS). While the AUA suggests a baseline PSA at the age of 40 with individualized testing interval depending on the patients' risk factors (see
http://www.auanet.org/content/press/press_releases/article.cfm?articleNo=178&WT.mc_id=EML2010AUA), the ACS recommends a careful discussion between doctors and patients regarding the pros and cons of PSA testing. (
http://www.cancer.org/docroot/CRI/content/CRI_2_6x_Prostate_Cancer_Early_Detection.asp?sitearea=&level=).
It is important to note that neither organizations state that PSA testing is not longer necessary. Both organization agree that additional research is necessary for us to find better screening tools for prostate cancer.